Australia's most trusted
source of pharma news
Saturday, 20 April 2024
Posted 24 January 2021 AM
In the competitive world of pharma it's rare for industry executives to publicly praise another company's medicine - but that's exactly what's happening with Pfizer's Covid antiviral Paxlovid.
Top members of the hierachy at both Lilly and Novartis have given Pfizer a pat on the back for its development of the much-heralded Covid treatment.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.